Toxicity and Local Irritation Action of the Biomedical Cell Product Anti-HER2-CAR-T-NK Upon Multiply Repeated Administration

CAR-cell therapy is a promising new method of cancer treatment. The biomedical cell product Anti-HER2-CAR-T-NK cells has been found safe in a course of intraperitoneal injection at a human-equivalent therapeutic dose in male and female ICR mice. The obtained information can help in the future to for...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal 2022-03, Vol.55 (12), p.1276-1281
Main Authors: Goryacheva, N. A., Rzhevskii, D. I., Slashcheva, G. A., Novikova, N. I., Kiselevskii, M. V., Chikileva, I. O., Vlasenko, R. Ya, Murashev, A. N., Bondarenko, D. A.
Format: Article
Language:English
Subjects:
Killer cells
Medical research
Medicine
Medicine, Experimental
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CAR-cell therapy is a promising new method of cancer treatment. The biomedical cell product Anti-HER2-CAR-T-NK cells has been found safe in a course of intraperitoneal injection at a human-equivalent therapeutic dose in male and female ICR mice. The obtained information can help in the future to form the basis of recommendations for preclinical studies of CAR-cell immunopreparations.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-022-02571-9